|
PH12013501201A1
(en)
*
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9868774B2
(en)
|
2011-10-20 |
2018-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
|
DK3473707T3
(da)
*
|
2012-05-25 |
2025-03-17 |
Cellectis |
Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
|
|
EP2862875B1
(en)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
|
ES2718903T3
(es)
|
2012-10-24 |
2019-07-05 |
Us Health |
Receptores de antígenos quiméricos M971
|
|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
ES2828982T3
(es)
|
2013-05-14 |
2021-05-28 |
Univ Texas |
Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US9808486B2
(en)
|
2013-08-30 |
2017-11-07 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
JPWO2015068847A1
(ja)
*
|
2013-11-11 |
2017-03-09 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
|
WO2015077789A2
(en)
|
2013-11-25 |
2015-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control hiv infection
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
|
CA3190002A1
(en)
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
CN103820393B
(zh)
*
|
2014-02-24 |
2016-09-07 |
西比曼生物科技（上海）有限公司 |
工程化cd20靶向性的nkt细胞及其制备方法和应用
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
EP3453406B1
(en)
*
|
2014-07-29 |
2021-04-14 |
Cellectis |
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
|
|
AU2015305531B2
(en)
|
2014-08-19 |
2021-05-20 |
Novartis Ag |
Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
|
|
IL250833B
(en)
|
2014-08-29 |
2022-09-01 |
Univ Texas |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
WO2016034666A1
(en)
|
2014-09-04 |
2016-03-10 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
ES2875057T3
(es)
|
2014-09-17 |
2021-11-08 |
Us Health |
Anticuerpos anti-CD276 (B7H3)
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
KR102122463B1
(ko)
|
2014-10-14 |
2020-06-15 |
할로자임, 아이엔씨 |
아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
|
|
JP2017535284A
(ja)
*
|
2014-11-05 |
2017-11-30 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
|
|
EP3215534B1
(en)
|
2014-11-05 |
2020-04-15 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
EP4632120A2
(en)
|
2014-11-11 |
2025-10-15 |
Chugai Seiyaku Kabushiki Kaisha |
Library of antigen-binding molecules including modified antibody variable region
|
|
KR102804498B1
(ko)
|
2014-12-03 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 방법 및 조성물
|
|
ES2921208T3
(es)
|
2014-12-08 |
2022-08-19 |
Us Health |
Receptores de antígeno quimérico anti-CD70
|
|
CN114107212A
(zh)
|
2014-12-24 |
2022-03-01 |
奥托路斯有限公司 |
细胞
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
|
AU2016212158B2
(en)
|
2015-01-26 |
2021-06-03 |
Allogene Therapeutics, Inc. |
mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
|
|
US20190388469A1
(en)
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
|
WO2016149578A1
(en)
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
|
HRP20200583T1
(hr)
|
2015-03-20 |
2020-07-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protutijela koja neutraliziraju gp120 i njihova upotreba
|
|
HRP20220893T1
(hr)
*
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
EP3283619B1
(en)
|
2015-04-17 |
2023-04-05 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP4424326A3
(en)
|
2015-06-10 |
2024-11-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
CN115925971A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
|
WO2016210447A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
WO2017035251A1
(en)
|
2015-08-25 |
2017-03-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cells modified to overexpress c-myb
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
US10562952B2
(en)
*
|
2015-09-10 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 chimeric antigen receptors
|
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
WO2017064222A1
(en)
|
2015-10-16 |
2017-04-20 |
Ludwig-Maximilians-Universität München |
Cxcr6-transduced t cells for targeted tumor therapy
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
US11059879B2
(en)
|
2015-10-27 |
2021-07-13 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
AU2016362129A1
(en)
|
2015-12-04 |
2018-06-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
WO2017139199A1
(en)
|
2016-02-10 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible arginase
|
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CN107298715B
(zh)
*
|
2016-04-15 |
2021-05-04 |
阿思科力(苏州)生物科技有限公司 |
Slit2D2-嵌合抗原受体及其应用
|
|
CN105968210B
(zh)
*
|
2016-05-13 |
2019-05-31 |
深圳生创精准医疗科技有限公司 |
靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
|
|
CN106167527A
(zh)
*
|
2016-06-13 |
2016-11-30 |
长沙郝怡雅医药科技有限公司 |
一种融合蛋白
|
|
GB201610512D0
(en)
*
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
|
CA3026858A1
(en)
|
2016-06-30 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Improved adoptive t-cell therapy
|
|
US11077178B2
(en)
|
2016-09-21 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
|
|
EP3516045A1
(en)
|
2016-09-23 |
2019-07-31 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
EP3519562A4
(en)
|
2016-09-29 |
2020-03-25 |
Nantkwest, Inc. |
NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
ES2939646T3
(es)
|
2016-10-13 |
2023-04-25 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
|
|
EP4092049A1
(en)
|
2016-10-20 |
2022-11-23 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
CN107964549B
(zh)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
靶向cd22的嵌合抗原受体及其用途
|
|
EP3555266B1
(en)
|
2016-12-13 |
2023-11-15 |
The United States of America, as Represented by The Secretary, Department of Health and Human Services |
Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
|
|
EP3565889B1
(en)
|
2017-01-06 |
2025-03-26 |
ImmunityBio, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
|
EP3882265B1
(en)
*
|
2017-01-09 |
2022-11-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CA3051481A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
JP7341900B2
(ja)
*
|
2017-03-03 |
2023-09-11 |
オブシディアン セラピューティクス， インコーポレイテッド |
免疫療法のためのｃｄ１９組成物及び方法
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US20210122831A1
(en)
*
|
2017-03-27 |
2021-04-29 |
Noile-Immune Biotech, Inc. |
Chimeric antigen receptor
|
|
DK3592379T3
(da)
|
2017-03-31 |
2024-06-03 |
Cellectis Sa |
Universelle anti-cd22-kimære antigenreceptor-modificerede immunceller
|
|
WO2018183842A1
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Standford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
|
AU2018251150B2
(en)
|
2017-04-13 |
2024-05-09 |
Albert-Ludwigs-Universität Freiburg |
New sequence specific reagents targeting CCR5 in primary hematopoietic cells
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
CN110650975B
(zh)
|
2017-05-15 |
2024-04-05 |
美国卫生和人力服务部 |
双顺反子嵌合抗原受体及其用途
|
|
US11566223B2
(en)
*
|
2017-06-01 |
2023-01-31 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
US12384830B2
(en)
|
2017-06-02 |
2025-08-12 |
Regents Of The University Of Minnesota |
Compositions and methods for improving immunotherapy
|
|
EP3635098B1
(en)
|
2017-06-05 |
2021-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T-cells modified to overexpress phf19
|
|
WO2018237325A1
(en)
*
|
2017-06-22 |
2018-12-27 |
University Of Southern California |
Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
|
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
|
AU2018292181B2
(en)
|
2017-06-30 |
2025-04-10 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
MX2020002901A
(es)
|
2017-09-19 |
2020-07-22 |
Massachusetts Inst Technology |
Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
EP4279584A3
(en)
*
|
2017-10-16 |
2024-03-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
|
CA3079264A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Intrexon Corporation |
Polypeptide compositions comprising spacers
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
EP3720963A4
(en)
|
2017-12-05 |
2021-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
|
|
WO2019117976A1
(en)
|
2017-12-17 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
CN111670246A
(zh)
|
2018-01-31 |
2020-09-15 |
南克维斯特公司 |
5%人白蛋白在洗涤和收获培养基中的用途
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
CN118374524A
(zh)
|
2018-02-09 |
2024-07-23 |
美国卫生和人力服务部 |
拴系白细胞介素-15和白细胞介素-21
|
|
AU2019216982B2
(en)
|
2018-02-11 |
2024-07-04 |
Memorial Sloan-Kettering Cancer Center |
Non-HLA restricted T cell receptors and uses thereof
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
WO2019173324A1
(en)
*
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
WO2019177986A1
(en)
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
TWI842703B
(zh)
*
|
2018-04-10 |
2024-05-21 |
美商安進公司 |
Dll3 的嵌合受體及其使用方法
|
|
JP7447014B2
(ja)
|
2018-04-13 |
2024-03-11 |
サンガモ セラピューティクス フランス |
インターロイキン２３受容体に特異的なキメラ抗原受容体
|
|
WO2019204269A1
(en)
|
2018-04-16 |
2019-10-24 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
|
CN118726256A
(zh)
|
2018-04-24 |
2024-10-01 |
美国卫生和人力服务部 |
使用羟基柠檬酸和/或其盐产生t细胞群体的方法
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
WO2019226521A1
(en)
|
2018-05-22 |
2019-11-28 |
Nantkwest, Inc. |
Basal media for growing nk-92 cells
|
|
CA3098471C
(en)
|
2018-05-22 |
2023-04-18 |
Nantkwest, Inc. |
Optimization of nk-92 cell growth using poloxamer
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US20210267190A1
(en)
|
2018-07-10 |
2021-09-02 |
Nantkwest, Inc. |
Cryopreservation
|
|
IL319500A
(en)
|
2018-07-10 |
2025-05-01 |
Immunitybio Inc |
Production of CIK NKT cells from cord blood
|
|
EP3820903A1
(en)
*
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
EP3830113A1
(en)
|
2018-08-01 |
2021-06-09 |
Nantkwest, Inc. |
Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
|
|
US12498363B2
(en)
|
2018-08-01 |
2025-12-16 |
Immunitybio, Inc. |
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
CN119752801A
(zh)
|
2018-08-01 |
2025-04-04 |
南克维斯特公司 |
用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
|
|
CA3106829A1
(en)
|
2018-08-03 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
CN109022363A
(zh)
*
|
2018-08-15 |
2018-12-18 |
马晓冬 |
一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
JP7401538B2
(ja)
|
2018-10-22 |
2023-12-19 |
シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド |
抗ｃｌｄｎ１８．２抗体およびその使用
|
|
US11547727B2
(en)
|
2018-11-06 |
2023-01-10 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
US12109238B2
(en)
|
2018-11-06 |
2024-10-08 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
CA3117936A1
(en)
|
2018-11-26 |
2020-06-04 |
Immunitybio, Inc. |
Il-2 dependent nk-92 cells with stable fc receptor expression
|
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
|
EP3935151A1
(en)
|
2019-03-08 |
2022-01-12 |
Klinikum der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
|
WO2020264019A1
(en)
|
2019-06-24 |
2020-12-30 |
Children's Hospital Los Angeles |
Bcl11b overexpression to enhance human thymopoiesis and t cell function
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
KR20220031054A
(ko)
|
2019-07-02 |
2022-03-11 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Egfrviii에 결합하는 단일클론 항체 및 이의 용도
|
|
AU2020315213A1
(en)
*
|
2019-07-17 |
2022-02-03 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
SG11202103981XA
(en)
|
2019-08-01 |
2021-05-28 |
Nantkwest Inc |
Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
|
|
EP4028413A1
(en)
|
2019-09-10 |
2022-07-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
|
CN114401989B
(zh)
|
2019-09-20 |
2024-02-09 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
CN115397866B
(zh)
|
2020-03-31 |
2025-10-31 |
中外制药株式会社 |
靶向dll3的多特异性抗原结合分子及其用途
|
|
US12448453B2
(en)
*
|
2020-04-02 |
2025-10-21 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human anti-human CD22 chimeric antigen receptor and application thereof
|
|
CN111484562B
(zh)
*
|
2020-04-25 |
2021-08-20 |
首都医科大学附属北京朝阳医院 |
一种靶向cd22蛋白的抗体、嵌合抗原受体和药物
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20230242643A1
(en)
|
2020-05-27 |
2023-08-03 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
|
EP4211228B1
(en)
|
2020-09-08 |
2025-11-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
WO2022104035A2
(en)
|
2020-11-13 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
EP4251742A4
(en)
|
2020-11-24 |
2025-01-08 |
Lyell Immunopharma, Inc. |
METHODS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING REGENERATED T CELLS
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
CA3201621A1
(en)
|
2020-12-03 |
2022-06-09 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
|
CA3212530A1
(en)
|
2021-03-05 |
2022-09-09 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-cldn6 antibody and use thereof
|
|
EP4352091A1
(en)
*
|
2021-05-27 |
2024-04-17 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified chimeric antigen receptor and use thereof
|
|
US20250295693A1
(en)
|
2021-08-18 |
2025-09-25 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023130040A2
(en)
|
2021-12-31 |
2023-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell therapy with vaccination as a combination immunotherapy against cancer
|
|
TW202340474A
(zh)
|
2022-01-11 |
2023-10-16 |
大陸商深圳市珈鈺生物科技有限公司 |
樹突細胞腫瘤疫苗和其用途
|
|
CN118256444A
(zh)
*
|
2022-04-26 |
2024-06-28 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
IL317568A
(en)
|
2022-06-10 |
2025-02-01 |
Res Found Dev |
Engineered FCRIIB Selective IgG1 FC Variants, and Their Uses
|
|
EP4653467A1
(en)
*
|
2023-01-19 |
2025-11-26 |
Wuhan Zhaozhi Biotechnology Co., Ltd. |
Car molecule, cell or exosome containing same, and use thereof
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|